Glivec and Central nervous system leukaemia - a phase IV clinical study of FDA data

Summary:

Central nervous system leukaemia is reported as a side effect among people who take Glivec (imatinib mesylate), especially for people who are male, 20-29 old, have been taking the drug for 1 - 6 months also take Diflucan, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Central nervous system leukaemia when taking Glivec. It is created by eHealthMe based on reports of 17,769 people who have side effects when taking Glivec from the FDA, and is updated regularly.

What is Glivec?

Glivec has active ingredients of imatinib mesylate. eHealthMe is studying from 17,777 Glivec users. Check the latest studies of Glivec.

What is Central nervous system leukaemia?

Central nervous system leukaemia (cancer of central nervous system) is found to be associated with 32 drugs and 86 conditions by eHealthMe. Check the latest studies of Central nervous system leukaemia.

On Jul, 10, 2026

17,769 people reported to have side effects when taking Glivec.
Among them, 22 people (0.12%) have Central nervous system leukaemia.

Could Glivec cause Central nervous system leukaemia?

Among these 22 people:

How long have people been on Glivec when they have Central nervous system leukaemia? *

What is the gender of people who have Central nervous system leukaemia when taking Glivec? *

female: 14.29 %
male: 85.71 %

What is the age of people who have Central nervous system leukaemia when taking Glivec? *

What are other drugs people take besides Glivec? *

What are other side effects people have besides Central nervous system leukaemia? *

Malignant Neoplasm Progression (cancer tumour came back): 7 people, 31.82%
Headache (pain in head): 6 people, 27.27%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 5 people, 22.73%
Blast Crisis In Myelogenous Leukaemia: 5 people, 22.73%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 5 people, 22.73%
Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 5 people, 22.73%
Hydrocephalus (water on the brain): 4 people, 18.18%
Cerebral Ventricle Dilatation (enlargement of ventricle of brain): 4 people, 18.18%
Staphylococcal Infection (an infection with staphylococcus bacteria): 4 people, 18.18%
Thrombocytopenia (decrease of platelets in blood): 4 people, 18.18%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 12 people, 54.55%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 11 people, 50.00%
Stomatitis (inflammation of mucous membrane of mouth): 3 people, 13.64%
Oral Pain: 3 people, 13.64%
Nasopharyngitis (inflammation of the nasopharynx): 3 people, 13.64%
Fever: 3 people, 13.64%
Eating Disorder: 3 people, 13.64%
Blood Bilirubin Increased: 3 people, 13.64%
Abdominal Discomfort: 3 people, 13.64%
Mouth Ulcers: 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Glivec and have Central nervous system leukaemia?

- Check whether Central nervous system leukaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glivec:

Glivec (17,777 reports)

Browse all side effects of Glivec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central nervous system leukaemia:

Central nervous system leukaemia (32 drugs)

Browse all the conditions that are associated with Central nervous system leukaemia:

Central nervous system leukaemia (86 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Glivec) and Glivec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.